Document is current

Article History

Received: 22 December 2025

Accepted: 14 March 2026

First Online: 21 March 2026

Declarations

:

: This observational study was conducted in accordance with the regulatory requirements and the ethical principles of the Declaration of Helsinki as adopted by the 18th World Medical Assembly. The study was approved by the Swedish Ethical Review Authority as The Swedish BioFINDER - Primary Care Study Dnr 2019–04320. An informed consent was signed and collected before enrolment in the study.

: N.A.

: NMC- reports a relationship with Biogen Inc that includes: consulting or advisory and speaking and lecture fees, a relationship with BioArctic AB that includes: consulting or advisory and speaking and lecture fees, a relationship with Eli Lilly and Company that includes: consulting or advisory and speaking and lecture fees, a relationship with Novo Nordisk Pharma Co Ltd that includes: consulting or advisory and speaking and lecture fees, a relationship with Merck & Co Inc that includes: consulting or advisory and speaking and lecture fees, a relationship with Owkin Inc that includes: consulting or advisory and speaking and lecture fees. SP- reports a relationship with BioArctic AB that includes: consulting or advisory and speaking and lecture fees, a relationship with Eisai Inc that includes: consulting or advisory and speaking and lecture fees, a relationship with Eli Lilly and Company that includes: consulting or advisory and speaking and lecture fees, reports a relationship with novo that includes: consulting or advisory and speaking and lecture fees, a relationship with Roche that includes: consulting or advisory and speaking and COI form lecture fees. SP serving as associate editor at JPAD OH reports a relationship with Eli Lilly and Company that includes: employment. RS- reports a relationship with Eli Lilly and Company that includes: consulting or advisory and speaking and lecture fees, a relationship with Novo Nordisk Pharma Co Ltd that includes: consulting or advisory and speaking and lecture fees, a relationship with Roche that includes: consulting or advisory and speaking and lecture fees, a relationship with Triolab that includes: consulting or advisory and speaking and lecture fees. SES- reports a relationship with Eisai Inc that includes: board membership, consulting or advisory, and speaking and lecture fees, a relationship with Novo Nordisk Inc that includes: board membership, consulting or advisory, and speaking and lecture fees, a relationship with Eli Lilly and Company that includes: speaking and lecture fees, a relationship with Medscape Education that includes: speaking and lecture fees, a relationship with peer reviwew that includes: speaking and lecture fees. SES is serving as a guest editor of a special issue of A&D:DADM on amyloid-targeted treatments. LC- reports a relationship with Novo Nordisk Inc that includes: equity or stocks, a relationship with Eli Lilly and Company that includes: equity or stocks. Other authors, declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.